Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction

Identifieur interne : 000482 ( PascalFrancis/Curation ); précédent : 000481; suivant : 000483

Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction

Auteurs : Tin-Yun Ho [Taïwan] ; Shih-Lu Wu [Taïwan] ; Jaw-Chyun Chen [Taïwan] ; Yen-Chiao Wei [Taïwan] ; Shin-Ei Cheng [Taïwan] ; Yung-Hsien Chang [Taïwan] ; Hsu-Jan Liu [Taïwan] ; Chien-Yun Hsiang [Taïwan]

Source :

RBID : Pascal:06-0217624

Descripteurs français

English descriptors

Abstract

Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The binding of SARS-CoV spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) is the first step in SARS-CoV infection. Therefore, we assayed the inhibitory effects of small peptides derived from S protein on the binding of S protein to ACE2 and on the S-protein-pseudotyped retrovirus infectivity. SP-4 (residues 192-203), SP-8 (residues 483-494), and SP-10 (residues 668-679) significantly blocked the interaction between S protein and ACE2 by biotinylated enzyme-linked immunosorbent assay, with IC50 values of 4.30 ± 2.18, 6.99 ± 0.71, and 1.88 ± 0.52 nmol, respectively. Peptide scanning suggested the region spanning residues 660-683 might act as a receptor-binding domain. SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. In conclusion, this is the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2. Our findings suggest that SP-10 may be developed as an anti-SARS-CoV agent for the treatment of SARS-CoV infection.
pA  
A01 01  1    @0 0166-3542
A02 01      @0 ARSRDR
A03   1    @0 Antivir. res.
A05       @2 69
A06       @2 2
A08 01  1  ENG  @1 Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction
A11 01  1    @1 HO (Tin-Yun)
A11 02  1    @1 WU (Shih-Lu)
A11 03  1    @1 CHEN (Jaw-Chyun)
A11 04  1    @1 WEI (Yen-Chiao)
A11 05  1    @1 CHENG (Shin-Ei)
A11 06  1    @1 CHANG (Yung-Hsien)
A11 07  1    @1 LIU (Hsu-Jan)
A11 08  1    @1 HSIANG (Chien-Yun)
A14 01      @1 Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University @2 Taichung @3 TWN @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.
A14 02      @1 Department of Biochemistry, China Medical University @2 Taichung @3 TWN @Z 2 aut.
A14 03      @1 Department of Microbiology, China Medical University, 91 Hsueh-Shih Road @2 Taichung 404 @3 TWN @Z 4 aut. @Z 8 aut.
A20       @1 70-76
A21       @1 2006
A23 01      @0 ENG
A43 01      @1 INIST @2 18839 @5 354000115127960030
A44       @0 0000 @1 © 2006 INIST-CNRS. All rights reserved.
A45       @0 1 p.1/4
A47 01  1    @0 06-0217624
A60       @1 P
A61       @0 A
A64 01  1    @0 Antiviral research
A66 01      @0 NLD
C01 01    ENG  @0 Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The binding of SARS-CoV spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) is the first step in SARS-CoV infection. Therefore, we assayed the inhibitory effects of small peptides derived from S protein on the binding of S protein to ACE2 and on the S-protein-pseudotyped retrovirus infectivity. SP-4 (residues 192-203), SP-8 (residues 483-494), and SP-10 (residues 668-679) significantly blocked the interaction between S protein and ACE2 by biotinylated enzyme-linked immunosorbent assay, with IC50 values of 4.30 ± 2.18, 6.99 ± 0.71, and 1.88 ± 0.52 nmol, respectively. Peptide scanning suggested the region spanning residues 660-683 might act as a receptor-binding domain. SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. In conclusion, this is the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2. Our findings suggest that SP-10 may be developed as an anti-SARS-CoV agent for the treatment of SARS-CoV infection.
C02 01  X    @0 002B02S05
C02 02  X    @0 002B05C02C
C03 01  X  FRE  @0 Activité biologique @5 01
C03 01  X  ENG  @0 Biological activity @5 01
C03 01  X  SPA  @0 Actividad biológica @5 01
C03 02  X  FRE  @0 Peptide @5 02
C03 02  X  ENG  @0 Peptides @5 02
C03 02  X  SPA  @0 Péptido @5 02
C03 03  X  FRE  @0 Coronavirus @2 NW @5 03
C03 03  X  ENG  @0 Coronavirus @2 NW @5 03
C03 03  X  SPA  @0 Coronavirus @2 NW @5 03
C03 04  X  FRE  @0 Syndrome respiratoire aigu sévère @2 NM @5 04
C03 04  X  ENG  @0 Severe acute respiratory syndrome @2 NM @5 04
C03 04  X  SPA  @0 Síndrome respiratorio agudo severo @2 NM @5 04
C03 05  X  FRE  @0 Protéine @5 05
C03 05  X  ENG  @0 Protein @5 05
C03 05  X  SPA  @0 Proteína @5 05
C03 06  X  FRE  @0 Peptidyl-dipeptidase A @2 FE @5 06
C03 06  X  ENG  @0 Peptidyl-dipeptidase A @2 FE @5 06
C03 06  X  SPA  @0 Peptidyl-dipeptidase A @2 FE @5 06
C03 07  X  FRE  @0 Interaction @5 07
C03 07  X  ENG  @0 Interaction @5 07
C03 07  X  SPA  @0 Interacción @5 07
C03 08  X  FRE  @0 Antiviral @5 08
C03 08  X  ENG  @0 Antiviral @5 08
C03 08  X  SPA  @0 Antiviral @5 08
C03 09  X  FRE  @0 Cellule Vero @4 INC @5 86
C07 01  X  FRE  @0 Coronaviridae @2 NW
C07 01  X  ENG  @0 Coronaviridae @2 NW
C07 01  X  SPA  @0 Coronaviridae @2 NW
C07 02  X  FRE  @0 Nidovirales @2 NW
C07 02  X  ENG  @0 Nidovirales @2 NW
C07 02  X  SPA  @0 Nidovirales @2 NW
C07 03  X  FRE  @0 Virus @2 NW
C07 03  X  ENG  @0 Virus @2 NW
C07 03  X  SPA  @0 Virus @2 NW
C07 04  X  FRE  @0 Virose
C07 04  X  ENG  @0 Viral disease
C07 04  X  SPA  @0 Virosis
C07 05  X  FRE  @0 Infection
C07 05  X  ENG  @0 Infection
C07 05  X  SPA  @0 Infección
C07 06  X  FRE  @0 Peptidyl-dipeptidases @2 FE
C07 06  X  ENG  @0 Peptidyl-dipeptidases @2 FE
C07 06  X  SPA  @0 Peptidyl-dipeptidases @2 FE
C07 07  X  FRE  @0 Peptidases @2 FE
C07 07  X  ENG  @0 Peptidases @2 FE
C07 07  X  SPA  @0 Peptidases @2 FE
C07 08  X  FRE  @0 Hydrolases @2 FE
C07 08  X  ENG  @0 Hydrolases @2 FE
C07 08  X  SPA  @0 Hydrolases @2 FE
C07 09  X  FRE  @0 Enzyme @2 FE
C07 09  X  ENG  @0 Enzyme @2 FE
C07 09  X  SPA  @0 Enzima @2 FE
C07 10  X  FRE  @0 Appareil respiratoire pathologie @5 37
C07 10  X  ENG  @0 Respiratory disease @5 37
C07 10  X  SPA  @0 Aparato respiratorio patología @5 37
C07 11  X  FRE  @0 Poumon pathologie @5 38
C07 11  X  ENG  @0 Lung disease @5 38
C07 11  X  SPA  @0 Pulmón patología @5 38
N21       @1 135

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:06-0217624

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction</title>
<author>
<name sortKey="Ho, Tin Yun" sort="Ho, Tin Yun" uniqKey="Ho T" first="Tin-Yun" last="Ho">Tin-Yun Ho</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Wu, Shih Lu" sort="Wu, Shih Lu" uniqKey="Wu S" first="Shih-Lu" last="Wu">Shih-Lu Wu</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Biochemistry, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Chen, Jaw Chyun" sort="Chen, Jaw Chyun" uniqKey="Chen J" first="Jaw-Chyun" last="Chen">Jaw-Chyun Chen</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Wei, Yen Chiao" sort="Wei, Yen Chiao" uniqKey="Wei Y" first="Yen-Chiao" last="Wei">Yen-Chiao Wei</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Microbiology, China Medical University, 91 Hsueh-Shih Road</s1>
<s2>Taichung 404</s2>
<s3>TWN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Cheng, Shin Ei" sort="Cheng, Shin Ei" uniqKey="Cheng S" first="Shin-Ei" last="Cheng">Shin-Ei Cheng</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Chang, Yung Hsien" sort="Chang, Yung Hsien" uniqKey="Chang Y" first="Yung-Hsien" last="Chang">Yung-Hsien Chang</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Liu, Hsu Jan" sort="Liu, Hsu Jan" uniqKey="Liu H" first="Hsu-Jan" last="Liu">Hsu-Jan Liu</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Hsiang, Chien Yun" sort="Hsiang, Chien Yun" uniqKey="Hsiang C" first="Chien-Yun" last="Hsiang">Chien-Yun Hsiang</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Microbiology, China Medical University, 91 Hsueh-Shih Road</s1>
<s2>Taichung 404</s2>
<s3>TWN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">06-0217624</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0217624 INIST</idno>
<idno type="RBID">Pascal:06-0217624</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000508</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000482</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction</title>
<author>
<name sortKey="Ho, Tin Yun" sort="Ho, Tin Yun" uniqKey="Ho T" first="Tin-Yun" last="Ho">Tin-Yun Ho</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Wu, Shih Lu" sort="Wu, Shih Lu" uniqKey="Wu S" first="Shih-Lu" last="Wu">Shih-Lu Wu</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Biochemistry, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Chen, Jaw Chyun" sort="Chen, Jaw Chyun" uniqKey="Chen J" first="Jaw-Chyun" last="Chen">Jaw-Chyun Chen</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Wei, Yen Chiao" sort="Wei, Yen Chiao" uniqKey="Wei Y" first="Yen-Chiao" last="Wei">Yen-Chiao Wei</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Microbiology, China Medical University, 91 Hsueh-Shih Road</s1>
<s2>Taichung 404</s2>
<s3>TWN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Cheng, Shin Ei" sort="Cheng, Shin Ei" uniqKey="Cheng S" first="Shin-Ei" last="Cheng">Shin-Ei Cheng</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Chang, Yung Hsien" sort="Chang, Yung Hsien" uniqKey="Chang Y" first="Yung-Hsien" last="Chang">Yung-Hsien Chang</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Liu, Hsu Jan" sort="Liu, Hsu Jan" uniqKey="Liu H" first="Hsu-Jan" last="Liu">Hsu-Jan Liu</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author>
<name sortKey="Hsiang, Chien Yun" sort="Hsiang, Chien Yun" uniqKey="Hsiang C" first="Chien-Yun" last="Hsiang">Chien-Yun Hsiang</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Microbiology, China Medical University, 91 Hsueh-Shih Road</s1>
<s2>Taichung 404</s2>
<s3>TWN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiviral</term>
<term>Biological activity</term>
<term>Coronavirus</term>
<term>Interaction</term>
<term>Peptides</term>
<term>Peptidyl-dipeptidase A</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Activité biologique</term>
<term>Peptide</term>
<term>Coronavirus</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Protéine</term>
<term>Peptidyl-dipeptidase A</term>
<term>Interaction</term>
<term>Antiviral</term>
<term>Cellule Vero</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The binding of SARS-CoV spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) is the first step in SARS-CoV infection. Therefore, we assayed the inhibitory effects of small peptides derived from S protein on the binding of S protein to ACE2 and on the S-protein-pseudotyped retrovirus infectivity. SP-4 (residues 192-203), SP-8 (residues 483-494), and SP-10 (residues 668-679) significantly blocked the interaction between S protein and ACE2 by biotinylated enzyme-linked immunosorbent assay, with IC
<sub>50</sub>
values of 4.30 ± 2.18, 6.99 ± 0.71, and 1.88 ± 0.52 nmol, respectively. Peptide scanning suggested the region spanning residues 660-683 might act as a receptor-binding domain. SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. In conclusion, this is the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2. Our findings suggest that SP-10 may be developed as an anti-SARS-CoV agent for the treatment of SARS-CoV infection.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0166-3542</s0>
</fA01>
<fA02 i1="01">
<s0>ARSRDR</s0>
</fA02>
<fA03 i2="1">
<s0>Antivir. res.</s0>
</fA03>
<fA05>
<s2>69</s2>
</fA05>
<fA06>
<s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>HO (Tin-Yun)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>WU (Shih-Lu)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>CHEN (Jaw-Chyun)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>WEI (Yen-Chiao)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>CHENG (Shin-Ei)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>CHANG (Yung-Hsien)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>LIU (Hsu-Jan)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>HSIANG (Chien-Yun)</s1>
</fA11>
<fA14 i1="01">
<s1>Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Biochemistry, China Medical University</s1>
<s2>Taichung</s2>
<s3>TWN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Department of Microbiology, China Medical University, 91 Hsueh-Shih Road</s1>
<s2>Taichung 404</s2>
<s3>TWN</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20>
<s1>70-76</s1>
</fA20>
<fA21>
<s1>2006</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>18839</s2>
<s5>354000115127960030</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>06-0217624</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Antiviral research</s0>
</fA64>
<fA66 i1="01">
<s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The binding of SARS-CoV spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) is the first step in SARS-CoV infection. Therefore, we assayed the inhibitory effects of small peptides derived from S protein on the binding of S protein to ACE2 and on the S-protein-pseudotyped retrovirus infectivity. SP-4 (residues 192-203), SP-8 (residues 483-494), and SP-10 (residues 668-679) significantly blocked the interaction between S protein and ACE2 by biotinylated enzyme-linked immunosorbent assay, with IC
<sub>50</sub>
values of 4.30 ± 2.18, 6.99 ± 0.71, and 1.88 ± 0.52 nmol, respectively. Peptide scanning suggested the region spanning residues 660-683 might act as a receptor-binding domain. SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. In conclusion, this is the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2. Our findings suggest that SP-10 may be developed as an anti-SARS-CoV agent for the treatment of SARS-CoV infection.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Activité biologique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Biological activity</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Actividad biológica</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Peptide</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Peptides</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Péptido</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Protéine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Protein</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Proteína</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Peptidyl-dipeptidase A</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Peptidyl-dipeptidase A</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Peptidyl-dipeptidase A</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Interaction</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Interaction</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Interacción</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Antiviral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Antiviral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Antiviral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Cellule Vero</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Virose</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Viral disease</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Virosis</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Infección</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Peptidyl-dipeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Peptidyl-dipeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Peptidyl-dipeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21>
<s1>135</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000482 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000482 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0217624
   |texte=   Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021